Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

21.97 +3.59 (+19.53%)
Official Closing Price Updated: 4:15 PM EDT, Jul 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
18 19 Next >
2 Magnificent Growth Stocks to Buy With $500
No need to break the bank to invest in promising stocks. 
Via The Motley Fool
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer. 
Via Benzinga
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
Bad news for one player does not always equal good news for another. 
Via The Motley Fool
Decoding Bearish Analog And The Warning Signs You Can't Ignore
A look at the bearish analog structure that the S&P 500 could be unfolding and the 3 warning signs you can't ignore. 
Via Talk Markets
Topics Stocks
The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition
Some of the best stocks to buy in February according to MarketMaster AI suggest that a major economic recovery is underway. 
Via InvestorPlace
Topics Artificial Intelligence
Assessing Sarepta Therapeutics: Insights From 12 Financial Analysts
Via Benzinga
A Closer Look at 14 Analyst Recommendations For Sarepta Therapeutics
Via Benzinga
The Latest Analyst Ratings for Sarepta Therapeutics
Via Benzinga
Sarepta Therapeutics' Next-Gen Duchenne Muscular Therapy Shows Efficacy At Less Frequent Dosing
Sarepta Therapeutics unveils results from MOMENTUM study's Phase 2 trial for SRP-5051, a next-gen PPMO treatment targeting Duchenne muscular dystrophy. 
Via Benzinga
Got $3,000? 3 Growth Stocks to Double Up On Right Now
There's more to stock picking than comparing risk and reward. Finding the right position size for a particular stock is also important. 
Via The Motley Fool
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
It's always tough to be compared to a giant. 
Via The Motley Fool
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today
One pundit feels there is solid potential in one of the company's more recently approved drugs. 
Via The Motley Fool
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market
In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for. 
Via InvestorPlace
Stocks Flip To Losses, Nvidia Defies Gravity, Bitcoin Pauses For A Breather: What's Driving Markets Tuesday?
Tuesday on Wall Street was marked by a subdued trend in major equity indices as investors remained cautious ahead of key inflation data scheduled for release on Thursday and the kick-off of the... 
Via Benzinga
Topics Economy
Could Sarepta Therapeutics Stock Help You Become a Millionaire?
Can this struggling stock turn its fortunes around? 
Via The Motley Fool
Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year
Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) reported preliminary FY23 net product  
Via Benzinga
Bumble (BMBL) Stock Pops as Elliott Builds a Stake in Rival Match
Bumble stock is rising on Tuesday as BMBL investors learn of a $1 billion investment in rival dating services company Match. 
Via InvestorPlace
Why Is Sarepta Therapeutics (SRPT) Stock Up Today?
Sarepta Therapeutics stock is rising higher on Tuesday as SRPT investors react to positive comments from company CEO Douglas Ingram. 
Via InvestorPlace
Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday. 
Via Benzinga
Topics Stocks
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
Last year wasn't great for either stock, but that's no reason to ignore them. 
Via The Motley Fool
Analyst Ratings for Sarepta Therapeutics
Via Benzinga
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. 
Via Benzinga
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech... 
Via Talk Markets
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction... 
Via Benzinga
3 Things About Sarepta Therapeutics Every Smart Investor Knows
Mastering this stock requires appreciating a few scientific nuances. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
Both develop medicines for rare diseases, and each aims to conquer a niche market. 
Via The Motley Fool
1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond
Many investors are bailing out, but that might be a mistake. 
Via The Motley Fool
My Take: 4 Strong Growth Stocks to Buy This Week
These strong stocks are still available at a great price. That may not be the case a whole lot longer. 
Via The Motley Fool
3 Monster Stocks in the Making
These stocks could grow much larger over the next few years. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback